Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatment

Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatment

ESR1 mutation (ESR1m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy for hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (...

全面介紹

Saved in:
書目詳細資料
Main Authors: Nicholas C. Turner, Cynthia Huang Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, X. Cynthia, Erica L. Mayer, Yeon Hee Park, Stephen B. Fox, Xiaochun Liu, Sasha McClain, François‐Clément Bidard
格式: Artigo
語言:英语
出版: 2023
在線閱讀:https://doi.org/10.2217/fon-2022-1196
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

因特網

https://doi.org/10.2217/fon-2022-1196

相似書籍